CAS: 217797-14-3; (3S,4R)-3-((Benzo[d][1,3]Dioxol-5-Yloxy)Methyl)-4-(4-Fluorophenyl)Piperidine Methanesulfonate
- 英文名称(3S,4R)-3-((Benzo[d][1,3]Dioxol-5-Yloxy)Methyl)-4-(4-Fluorophenyl)Piperidine Methanesulfonate
- 中文名称甲磺酸帕罗西汀
- IUPAC名称(3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate
- 其它别名Carboxiamidotriazol; Paroxetine Mesilate [who-Dd]; (3S,4R)-3-((Benzo[d][1,3]Dioxol-5-Yloxy)Methyl)-4-(4-Fluorophenyl)Piperidine Methanesulfonate; 5,6Beta-Epoxy-Cholesterol; Paroxetine Mesylate (Usan); Piperidin
- CAS编号217797-14-3
- EINECS号:688-144-6
- FDA UNII编号:M711N184JE
- 分子式:C20H24FNO6S分子量:425.48
- 产品CID: 1135190
- 同类组份化合物CAS61869-08-7 (free base)64006-44-6 (maleate)78246-49-8 (HCl)72471-80-8 (acetate)217797-14-3 (mesylate)110429-35-1 (HCl hydrate)
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
物理性质
- 沸点453.6 °C at 760 mmHg
- 闪点189.2 °C
- PSA:102.47
- LogP:4.101
- 蒸汽压2.03E-08mmHg at 25°C
- 溶解性DMSO: 85 mg/mL (199.78 Mm);
- 外观形态粉末
- 储存条件储存在 -20°C
- 产品应用该化合物是一种强效且最具体选择性的血清素(5-羟基甲胺,5-HT)再摄取抑制剂(SSRIS)之一. 它对ST(SERROTONIN运输器/SERT)具有高度亲和性. 帕鲁克辛会与预先合成合成的血色素运输器复合体捆绑在一起,导致综合体出现负动静调节,从而阻塞了前合成运输器对血清酮的重新采集. 松克辛HCL 也表现出了对诱杀性乙酰胆碱受体的高度亲近性.
MSDS等安全信息
- GHS象形图
- GHS符号GHS08 & GHS07;
注释: Health hazard & Exclamation mark - 危险类别急性毒性 类别4(经口)
生殖毒性 类别2
特定目标器官毒性 - 单次接触 类别3 - 警示词Warning(警告)
- 危险描述H302 |吞咽有害.
H361 |怀疑对生育能力或胎儿造成损害.
H336 |可能引起嗜睡或头晕. - 防范说明P264-P270-P301+P312-P330-P501
- 安全声明Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown.
欧盟法规
C&L通报上下游产品
CAS号253768-88-6 phenyl (3S,4R)-...合成工艺路线路线简述
📜N-苯氧羰基帕罗西汀置于氢氧化钾,甲烷磺酸体系中,用 甲苯 用作溶剂,化学反应生成甲磺酸帕罗西汀
参考文献:Us6063927
标题:Us6063927
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2905121000-正丙醇
2907210001-间苯二酚 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-6686473-B2
优先权日:2001-02-21
标题:Process for the production of paroxetine
发明人：LEMMENS JACOBUS M; PETERS THEODORUS H A; PICHA FRANTISEK
权利人:SYNTHON BCT TECHNOLOGIES LLC
摘要:The synthesis of paroxetine can be made more convenient by using a solvent system comprising an aliphatic alcohol and a hydrocarbon co-solvent. The solvent system is used particularly in the hydrolysis of paroxetine phenylcarbamate and preferably uses butanol and toluene as the system.
专利号:EP-1286965-B1
优先权日:2000-05-12
标题 :Piperidine compounds and process for providing such
发明人：PETERS THEODORUS HENDRICUS ANT; LEMMENS JACOBUS MARIA; SLANINA PAVEL
权利人:SYNTHON BV
摘要:The tosylate ester of the formula (6) and its salts, are convenient intermediates in the synthesis of paroxetine.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Wang Y, Zhang A, Dilinuer A, Hao L, Hu Z, Jia W. Meta-analysis of acupuncture combined with paroxetine in the treatment of depression. Am J Transl Res. 2022 Dec 15;14(12):8429-8436.
2: Zeng M, Gong A, Wu Z. Paroxetine combined with traditional chinese medicine prescriptions in the treatment of postpartum depression: A systematic review of randomized controlled trials. Front Neuroendocrinol. 2022 Oct;67:101019. doi: 10.1016/j.yfrne.2022.101019. Epub 2022 Aug 1. 2006–. Paroxetine. 2022 May 15.
14:353-361. doi: 10.2147/IJWH.S282396.
合成参考文献
参考文献:10.5664/jcsm.5582
摘要:Lee K, Baron K, Soca R, Attarian H. The Prevalence and Characteristics of REM Sleep without Atonia (RSWA) in Patients Taking Antidepressants. J Clin Sleep Med. 2016 Mar;12(3):351–5.
📝 需求与反馈
尽可能描述清楚需求与问题信息
